Back to top
more

Entrada Therapeutics (TRDA)

(Real Time Quote from BATS)

$15.59 USD

15.59
61,728

+0.03 (0.19%)

Updated Jul 10, 2024 02:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (68 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

AstraZeneca (AZN) to Discontinue Two Studies on Lokelma

Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.

bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How

bluebird bio (BLUE) rises 25.6% in past thirty days on upbeat earnings results and promising progress with its approved therapies.

Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data

Immunovant (IMVT) posts encouraging initial results from the 600 mg MAD cohort of its early-stage study on IMVT-1402. Stock rises.

SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug

The FDA approves SpringWorks' (SWTX) Ogsiveo (nirogacestat) for the treatment of adult patients with desmoid tumors. Shares rise.

Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study

Xenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline candidate, XEN1101, for treating moderate-to-severe major depressive disorder. Stock rises.

TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug

The FDA clears TC BioPharm's (TCBP) investigational new drug application seeking approval to begin a clinical study on its pipeline candidate, TCB008, for treating acute myeloid leukemia. Stock declines.

Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug

Despite providing additional information, the FDA declines to lift the clinical hold on Entrada's (TRDA) regulatory filing seeking approval to start studies on its DMD drug in the United States.

Biotech Stock Roundup: BMY, TSVT Down on Setback, TRDA, MOR Offer Updates

Regulatory setback for Bristol Myers (BMY) and other updates are in focus in the biotech sector.

Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) delivered earnings and revenue surprises of 285.45% and 168.23%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) delivered earnings and revenue surprises of -81.40% and 7.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

New Strong Buy Stocks for July 21st

TRDA, LPRO, TBBK, BMTX and MOTS have been added to the Zacks Rank #1 (Strong Buy) List on July 21, 2023.

Ekta Bagri headshot

Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More

Pipeline updates from Madrigal (MDGL) and Entrada (TRDA) are the key highlights from the biotech sector during the past week.

Entrada (TRDA) Down on Regulatory Update for DMD Candidate

Entrada (TRDA) plunges on clinical hold notice from the FDA regarding its Investigational New Drug Application (IND) for Duchenne muscular dystrophy (DMD) candidate.

Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More

Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week.

Entrada (TRDA) Surges on Collaboration With Vertex for DMI

Entrada (TRDA) gains from its collaboration deal with Vertex to discover and develop Endosomal Escape Vehicle (EEV) therapeutics for DM1.